A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390 · PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company · Conditions: Atherosclerosis Cardiovascular Disease, Chronic Kidney

By Priya Raman · Science Reporter

Nov 4 07:00 ETSource: ClinicalTrials.gov

From the source

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390 · PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company · Conditions: Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07241390